39 studies found for:    breast,cancer,PARP
Show Display Options
Rank Status Study
1 Active, not recruiting AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer
Conditions: Breast Cancer;   Ovarian Cancer
Intervention: Drug: AZ2281 + Carboplatin
2 Active, not recruiting PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
Condition: Breast Cancer
Interventions: Drug: Cisplatin;   Drug: Rucaparib
3 Active, not recruiting Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer
Conditions: brca1 Mutation Carrier;   brca2 Mutation Carrier;   Breast Cancer;   Ovarian Cancer
Interventions: Drug: rucaparib (CO-338; formally AG-014699 or PF-01367338);   Genetic: protein expression analysis;   Genetic: western blotting;   Other: immunohistochemistry staining method;   Other: liquid chromatography;   Other: mass spectrometry;   Other: pharmacological study
4 Recruiting An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors
Conditions: Malignant Solid Tumour;   Ovarian Cancer;   Triple Negative Breast Cancer;   Advanced Melanoma;   B-cell Malignancy, Low-grade
Interventions: Drug: E7449 alone;   Drug: E7449 plus TMZ;   Drug: E7449 plus carboplatin and paclitaxel
5 Recruiting Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers
Conditions: Mixed Muellerian Cancer;   Cervical Cancer;   Ovarian Cancer;   Breast Cancer;   Primary Peritoneal Cancer;   Fallopian Tube Cancer;   Endometrial Cancer;   Carcinosarcoma
Interventions: Drug: Carboplatin;   Drug: Olaparib
6 Active, not recruiting Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Breast Cancer
Condition: Breast Neoplasms
Intervention: Drug: KU-0059436 (AZD2281) (PARP inhibitor)
7 Recruiting Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations
Conditions: Advanced Ovarian Cancer;   Primary Peritoneal Cancer;   Advanced Breast Cancer;   Advanced Solid Tumors
Intervention: Drug: BMN 673
8 Active, not recruiting ABT-888 With Cyclophosphamide in Refractory BRCA-Positive Ovarian, Primary Peritoneal or Ovarian High-Grade Serous Carcinoma, Fallopian Tube Cancer, Triple-Negative Breast Cancer, and Low-Grade Non-Hodgkin s Lymphoma
Conditions: Ovarian;   Primary Peritoneal;   Serous Carcinoma;   Triple-Negative Breast;   Fallopian Tube
Intervention: Drug: ABT-888 + Cyclophospharmide
9 Recruiting A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)
Conditions: Breast Neoplasms;   BRCA 1 Gene Mutation;   BRCA 2 Gene Mutation
Interventions: Drug: talazoparib;   Drug: Physician's-Choice
10 Recruiting A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Drug: Veliparib;   Drug: Carboplatin;   Drug: Paclitaxel;   Other: Placebo
11 Active, not recruiting A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
Conditions: Estrogen Receptor Negative (ER-Negative) Breast Cancer;   Progesterone Receptor Negative (PR-Negative) Breast Cancer;   Human Epidermal Growth Factor Receptor 2 Negative (HER2-Negative) Breast Cancer;   Brain Metastases
Intervention: Drug: INIPARIB + irinotecan
12 Active, not recruiting Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer Patients
Condition: Breast Cancer Female
Interventions: Drug: paclitaxel;   Drug: Iniparib (SAR2405550 -BSI-201)
13 Completed A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer
Condition: Triple Negative Breast Cancer
Intervention: Drug: gemcitabine plus carboplatin plus BSI-201
14 Active, not recruiting
Has Results
Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast Cancer
Conditions: Ovarian Carcinoma;   Breast Cancer
Intervention: Drug: AZD2281
15 Recruiting Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Male Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Recurrent Breast Cancer;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: veliparib;   Drug: pegylated liposomal doxorubicin hydrochloride;   Other: pharmacological study;   Other: laboratory biomarker analysis
16 Recruiting Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Papillary Serous Carcinoma;   Ovarian Serous Cystadenocarcinoma;   Progesterone Receptor-negative Breast Cancer;   Recurrent Breast Cancer;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer;   Triple-negative Breast Cancer
Interventions: Drug: olaparib;   Drug: cediranib maleate;   Other: laboratory biomarker analysis
17 Not yet recruiting mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian Cancer
Conditions: Breast Cancer;   Malignant Female Reproductive System Neoplasm
Interventions: Drug: Olaparib;   Drug: AZD2014;   Drug: AZD5363
18 Active, not recruiting ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer
Conditions: Breast Cancer;   Metastatic Breast Cancer;   BRCA1 or BRCA2 Associated Breast Cancer
Interventions: Drug: ABT-888;   Drug: temozolomide
19 Recruiting Phase I of BKM120/Olaparib for Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Conditions: Ovarian Cancer;   Breast Cancer
Intervention: Drug: BKM120 and Olaparib
20 Active, not recruiting Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel
Conditions: Triple Negative Metastatic Breast Cancer;   Advanced Ovarian Cancer;   Carboplatin;   Paclitaxel
Interventions: Drug: KU-0059436 (AZD2281)(PARP inhibitor);   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Paclitaxel + Carboplatin

Previous Page Studies Shown (1-20) Next Page (21-39) Show next page of results
Indicates status has not been verified in more than two years